Skip to main content

Diagnosis, Clinical Work Up, TNM Classification, Markers

  • Chapter
  • First Online:
Management of Prostate Cancer

Abstract

Prostate cancer (PCa) is the most common malignancy in developed countries, and the incidence is rapidly rising. Today, early detection is mostly induced by a large prescription of prostate-specific antigen (PSA) blood test. Although PSA remains the gold standard for diagnosis, clinical rectal examination is essential for staging prostate cancer and deciding treatment.

In this chapter, we give an overview on utilization of PSA to improve the sensibility and specificity of the test during early diagnosis. We also discuss the place of new molecular isoforms of PSA, novel blood, urine, and tissue markers useful for screening.

Finally, limits and performance of multimodal MRI as a diagnostic tool of PCa are reviewed as this imaging study is more and more useful, giving meaning to new prostate biopsy techniques and focal therapy protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aigner F, Pallwein L, Junker D et al (2010) Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4.00 ng/ml or less. J Urol 184:913–917

    Article  PubMed  Google Scholar 

  • Aubin SMJ, Reid J et al (2010) PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride reduce trial. J Urol 184:1947–1952

    Article  PubMed  Google Scholar 

  • Auprich M, Haese A, Walz J (2010) External validation of urinary pca3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 58:727–732

    Article  PubMed  Google Scholar 

  • Auprich M, Bjartell A, Chun FK et al (2011) Contemporary role of PC3 in the management of prostate cancer. Eur Urol 60:1045–1054

    Google Scholar 

  • Barry MJ, Fowler FJ, O’Leary M et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia: the measurement committee of the American Urological Association. J Urol 148(5):1549–1557

    CAS  PubMed  Google Scholar 

  • Beduschi MC, Oesterling JE (2007) Prostate-specific antigen density. Urol Clin North Am 24(2):323–332

    Article  Google Scholar 

  • Benson MC, Whang IS, Pantuck A et al (1992) The use of prostate specific density: a means distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147:817–821

    CAS  PubMed  Google Scholar 

  • Beuzeboc P, Soulie M, Richaud P et al (2009) Gènes de fusion et cancer de la prostate. De la découverte à la valeur pronostique et aux perspectives thérapeutiques. Prog Urol 19:819–824

    Article  CAS  PubMed  Google Scholar 

  • Canto EI, Singh H, Shariat S (2004) Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 63:905–911

    Article  PubMed  Google Scholar 

  • Cao DL, Ye DW, Zhang HL, Wang YX et al (2010) A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 71:700–710

    Article  PubMed  Google Scholar 

  • Carter HB, Pearson JD, Metter EJ et al (1992) Longitudinal evaluation of prostate specific antigen levels in men with or without prostate cancer. JAMA 267(16):2215–2220

    Article  CAS  PubMed  Google Scholar 

  • Catalona WJ, Partin AW (1998) Use of the percentage of free prostatic-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 279(19):1542–1547

    Article  CAS  PubMed  Google Scholar 

  • Catalona WJ, Partin AW, Sanda MG et al (2011) A multicenter study of [−2]pro-prostate specific antigen ­combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185:1650–1655

    Article  CAS  PubMed  Google Scholar 

  • Chun FK, De la Taille A (2009) Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 56:659–668

    Article  PubMed  Google Scholar 

  • De la Taille A, Irani J et al (2011) Clinical evaluation of the pca3 assay in guiding initial biopsy decisions. J Urol 185:2119–2125

    Article  PubMed  Google Scholar 

  • Demichelis F, Fall K, Perner S et al (2007) TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:4596–4599

    Article  CAS  PubMed  Google Scholar 

  • Deras IL, Aubin SMJ, Blase A et al (2008) PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179:1587–1592

    Article  PubMed  Google Scholar 

  • Diamandis EP (2007) Point: EPCA-2 a promising new serum biomarker for prostate cancer? Clin Chem 40:1437–1439

    CAS  Google Scholar 

  • Dickinson L, Ahmed HU (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59:477–494

    Article  PubMed  Google Scholar 

  • Djavan B, Kazzazi A, Dulabon L et al (2011) Diagnostic strategies for prostate cancer. Eur Urol 10:e26–e37

    Article  CAS  Google Scholar 

  • Ficarra V, Novara G, Zattoni F (2010) The role of the prostate cancer antigen 3 (pca3) test for the diagnosis of prostate cancer in the era of opportunistic prostate-specific antigen screening. Eur Urol 58:482–484

    Article  PubMed  Google Scholar 

  • Gomella LG, El-Gabry EA, Strup S et al (2001) Ultrasound contrast agents for prostate imaging and biopsy. Urol Oncol 6:189–192

    Article  Google Scholar 

  • Guazzoni G, Nava L, Lazzeri M et al (2011) Prostate-specific antigen (psa) isoform p2psa significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total psa between 2.0 And 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 60:214–222

    Article  CAS  PubMed  Google Scholar 

  • Haese A, De la Taille A et al (2008) Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54:1081–1088

    Article  PubMed  Google Scholar 

  • Hamdy FC, Roupret M (2008) The PCPT trial. Prog Urol 18(3):540–543

    Google Scholar 

  • Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71

    Article  PubMed  Google Scholar 

  • Jansen FH, Van Schaik RHN, Kurstjens J et al (2010) Prostate-specific antigen (psa) isoform p2psa in combination with total psa and free psa improves diagnostic accuracy in prostate cancer detection. Eur Urol 57:921–927

    Article  CAS  PubMed  Google Scholar 

  • Jolivet-Reynaud C, Michel S, Ott C (2008) Detection of prostate-specific antigen forms and other kallikreins in prostate cancer. Med Nucl 32:24–30

    Google Scholar 

  • Kobus T, Hambrock T, Hulsbergen-vandeKaa CA et al (2011) In vivo assessment to prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 t with an endorectal coil. Eur Urol 60:1074–1080

    Article  PubMed  Google Scholar 

  • Kozlowskia P, Chang SD, Meng R et al (2010) Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3 T - quantitative correlation with biopsy. Magn Reson Imaging 28:621–628

    Article  Google Scholar 

  • Leman ES, Cannon GW et al (2007) EPCA-2: a highly specific serum marker for prostate cancer. Urology 69(4):714–720

    Article  PubMed  Google Scholar 

  • Mikolajczyk SD, Millar LS, Wang TJ et al (2000) “BPSA”, a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55:41–45

    Article  CAS  PubMed  Google Scholar 

  • Mikolajczyk SD, Linton HJ et al (2004) Serum bpsa outperforms both total psa and free psa as a predictor of prostatic enlargement in men without prostate cancer. Urology 63:905–911

    Article  PubMed  Google Scholar 

  • Morelli G, Pagni R, Mariani C (2011) Results of vardenafil mediated power Doppler ultrasound contrast enhanced ultrasound and systematic random biopsies to detect prostate cancer. J Urol 185:2126–2131

    Article  CAS  PubMed  Google Scholar 

  • Ngo TC, Turnbull BB, Lavori PW et al (2011) The prostate cancer risk calculator from the prostate cancer prevention trial underestimates the risk of high grade cancer in contemporary referral patients. J Urol 185:483–488

    Article  PubMed  Google Scholar 

  • Parekh DJ, Ankerst DP, Higgins BA (2006) External validation of the prostate cancer prevention trial risk calculator in a screened population. Urology 68:1152–1155

    Article  PubMed  Google Scholar 

  • Parekh DJ, Ankerst DP et al (2007) Biomarkers for prostate cancer detection. J Urol 178:2252–2259

    Article  CAS  PubMed  Google Scholar 

  • Partin AW, Brawer MK, Bartsch G (2003) Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 170:1787–1791

    Article  PubMed  Google Scholar 

  • Paul B, Dhir R, Landsittel D, Hitchens MR et al (2005) Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 65:4097–4100

    Article  CAS  PubMed  Google Scholar 

  • Payne H, Cornford P et al (2011) Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol 29:593–601

    Article  PubMed  Google Scholar 

  • Perner S, Demichelis F, Beroukhim R et al (2006) TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66(17):8337–8341

    Article  CAS  PubMed  Google Scholar 

  • Pondman KM, Futterer JJ, Ten Haken B et al (2008) MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol 54:517–527

    Article  PubMed  Google Scholar 

  • Raymond C Rosen, Alan Riley, Gorm Wagner et al (1997) The International Index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49(6):823–830

    Google Scholar 

  • Remzi M, Haese A, Van Poppel H et al (2010) Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer? BJU Int 106(8):1138–1142

    Article  PubMed  Google Scholar 

  • Roddam AW, Duffy MJ, Hamdy FC et al (2005) Use of prostate-specific antigen (psa) isoforms for the detection of prostate cancer in men with a psa level of 2 to 10 ng/ml: systematic review and meta-analysis. Eur Urol 48:386–399

    Article  CAS  PubMed  Google Scholar 

  • Roobol MJ (2011) Prostate cancer biomarkers to improve risk stratification: is our knowledge of prostate cancer sufficient to spare prostate biopsies safely? Eur Urol 60:223–225

    Article  PubMed  Google Scholar 

  • Roobol MJ, Schroder FH et al (2010) Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in pre screened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 58:475–481

    Article  CAS  PubMed  Google Scholar 

  • Roy C, Pasquali R, Matau A et al (2010) The role of diffusion 3 –Tesla MRI in detecting prostate cancer before needle biopsy: multiparametric study of 111 patients. J Radiol 91:1121–1128

    Article  CAS  PubMed  Google Scholar 

  • Salami SS, Schmidt F, Laxman B et al (2011) Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol

    Google Scholar 

  • Salomon G, Kollerman J, Thederan I et al (2008) Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur Urol 54:1354–1362

    Article  PubMed  Google Scholar 

  • Scherra MK, Seitz M, Müller-Lissea UG (2010) MR-perfusion (MRP) and diffusion-weighted imaging (DWI) in prostate cancer: quantitative and model-based gadobenate dimeglumine MRP parameters in detection of prostate cancer. Eur J Radiol 76:359–366

    Article  Google Scholar 

  • Schostak M, Schwall GP, Poznanovic S et al (2009) Annexin A3 in urine: a highly specific non-invasive marker for prostate cancer early detection. J Urol 191:343–353

    Article  Google Scholar 

  • Schroder F, Carter HB et al (2008) Early detection of prostate cancer in 2007 part 1: PSA and PSA kinetics. Eur Urol 53:468–477

    Article  PubMed  Google Scholar 

  • Sciarra A, Barentsz J, Bjartell A et al (2011) Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 59:962–977

    Article  PubMed  Google Scholar 

  • Sokoll LJ, Wang Y et al (2008) [−2] proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 180:539–543

    Article  CAS  PubMed  Google Scholar 

  • Sreekumar A, Poisson LM, Rajendiranl TM et al (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457:910–915

    Article  CAS  PubMed  Google Scholar 

  • Steuber T, O’Brien MF, Lilja H (2008) Serum markers for prostate cancer: a rational approach to the literature. Eur Urol 54:31–40

    Article  CAS  PubMed  Google Scholar 

  • Teillac P, Abrahamsson PA (2006) The prostate cancer prevention trial and its implications for clinical practice: a European consensus. Eur Urol Suppl 5:640–646

    Article  Google Scholar 

  • Tomlins SA, Aubin SMJ, Siddiqui J et al (2011) Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3(94):1–12

    Article  Google Scholar 

  • Vlaeminck-Guillem V, Devonec M, Colombel M et al (2011) Urinary PCA3 score predicts prostate cancer multifocality. J Urol 185:1234–1239

    Article  PubMed  Google Scholar 

  • Walz A, Marcyb M, Maubonc T (2011) Real time elastography in the diagnosis of prostate cancer: comparison of preoperative imaging and histology after radical prostatectomy. Prog Urol 21:925–931

    Article  CAS  PubMed  Google Scholar 

  • Whitman EJ, Groskopf J et al (2008) PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 180:1975–1979

    Article  PubMed  Google Scholar 

  • Wink M, Frauscher F, Cosgrove D et al (2008) Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project. Eur Urol 54:982–993

    Article  PubMed  Google Scholar 

  • Zhigang Z, Guohua Z, Wen Z (2010) Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection, of the prostate for benign prostatic hyperplasia. Prostate 70:1788–1798

    Google Scholar 

  • Zhigang Z, Wenjing M, Guohua Z et al (2011) Serum early prostate cancer antigen (EPCA) level and its association with decrease progression in prostate cancer in a Chinese population. PLoS One 6(5):e19284

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Jean-Luc Descotes Ph.D., D.Sc. or Anne-Sophie Gauchez Ph.D., D. Ph. .

Editor information

Editors and Affiliations

Appendices

Appendix A

 

Not at all

Less than 1 time in 5

Less than half the time

About half the time

More than half the time

Almost always

1. Over the past month, how often have you had a sensation of not emptying your bladder completely after you finished urinating?

0

1

2

3

4

5

2. Over the past month, how often have you had to urinate again less than 2 h after you finished urinating?

0

1

2

3

4

5

3. Over the past month, how often have you found you stopped and started again several times when you urinated?

0

1

2

3

4

5

4. Over the past month, how often have you found it difficult to postpone urination?

0

1

2

3

4

5

5. Over the past month, how often have you had a weak urinary stream?

0

1

2

3

4

5

6. Over the past month, how often have you had to push or strain to begin urination?

None

1 time

2 times

3 times

4 times

5 times or more

7. Over the past month, how many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning?

0

1

2

3

4

5

Total Symptom Score

The International Prostate Symptom Score uses the same seven questions as the AUA Symptom Index (presented above) with the addition of the following Disease Specific Quality of Life Question (bother score) scored on a scale from 0 to 6 points (delighted to terrible):

If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?

Individual Items of International Index of Erectile Function Questionnaire and Response Options (US Version)

Question/Response Options

  • Q1:How often were you able to get an erection during sexual activity?

    • 0  =  No sexual activity

    • 1  =  Almost never/never

    • 2  =  A few times (much less than half the time)

    • 3  =  Sometimes (about half the time)

    • 4  =  Most times (much more than half the time)

    • 5  =  Almost always/always

  • Q2:When you had erections with sexual stimulation, how often were your erections hard enough for penetration?

    • 0  =  No sexual activity

    • 1  =  Almost never/never

    • 2  =  A few times (much less than half the time)

    • 3  =  Sometimes (about half the time)

    • 4  =  Most times (much more than half the time)

    • 5  =  Almost always/always

  • Q3:When you attempted sexual intercourse, how often were you able to penetrate (enter) your partner?

    • 0  =  Did not attempt intercourse

    • I  =  Almost never/never

    • 2  =  A few times (much less than half the time)

    • 3  =  Sometimes (about half the time)

    • 4  =  Most times (much more than half the time)

    • 5  =  Almost always/always

  • Q4:During sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner?

    • 0  =  Did not attempt intercourse

    • I  =  Almost never/never

    • 2  =  A few times (much less than half the time)

    • 3  =  Sometimes (about half the time)

    • 4  =  Most times (much more than half the time)

    • 5  =  Almost always/always

  • Q5:During sexual intercourse, how difficult was it to maintain your erection to completion of intercourse?

    • 0  =  Did not attempt intercourse

    • 1  =  Extremely difficult

    • 2  =  Very difficult

    • 3  =  Difficult

    • 4  =  Slightly difficult

    • 5  =  Not difficult

  • Q6How many times have you attempted sexual intercourse?

    • 0  =  No attempts

    • 1  =  One to two attempts

    • 2  =  Three to four attempts

    • 3  =  Five to six attempts

    • 4  =  Seven to ten attempts

    • 5  =  Eleven  +  attempts

  • Q7:When you attempted sexual intercourse, how often was it satisfactory for you?

    • 0  =  Did not attempt intercourse

    • 1  =  Almost never/never

    • 2  =  A few times (much less than half the time)

    • 3  =  Sometimes (about half the time)

    • 4  =  Most times (much more than half the time)

    • 5  =  Almost always/always

(Raymond et al. 1997)

Appendix C

Category

Weights of the comorbid conditions

Myocardial infarct

1

Congestive heart failure

1

Peripherical vascular disease

1

Cerebrovascular disease

1

Dementia

1

Chronic pulmonary disease

1

Connective tissue disease

1

Ulcer disease

1

Mild liver disease

1

Diabetes

1

Hemiplegia

2

Moderate or severe renal disease

2

Diabetes  +  end organ damage

2

Any tumor

2

Leukemia

2

Lymphoma

2

Moderate or severe liver disease

3

Metastatic solid tumor

6

AIDS

6

The 19 conditions contributing to conventional Charlson score

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Descotes, JL., Gauchez, AS. (2012). Diagnosis, Clinical Work Up, TNM Classification, Markers. In: Bolla, M., van Poppel, H. (eds) Management of Prostate Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27597-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-27597-5_6

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-27596-8

  • Online ISBN: 978-3-642-27597-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics